Cost effectiveness of an adherence-improving programme in hypertensive patients

PharmacoEconomics

Volumn 25, Issue 3, 2007, Pages 239-251

  Brunenberg, Danielle E M ^a   Wetzels, Gwenn E C ^b   Nelemans, Patricia J ^b   Dirksen, Carmen D ^a   Severens, Johan L ^a,b   Stoffers, Henri E J H ^b   Schouten, Jan S A G ^a   Prins, Martin H ^a,b   De Leeuw, Peter W ^a   Joore, Manuela A ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; GENERAL PRACTICE; HEALTH PROGRAM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; QUALITY OF LIFE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847701236     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725030-00006     Document Type: Article

References (53)

1. Hunt JS, Siemienczuk J, Touchette D, et al. Impact of educational mailing on the BP of primary care patients with mild hypertension. J Gen Intern Med 2004; 19: 925-30
2. Urquhart J. Patient non-compliance with drug regimens: measurement, clinical correlates, economic impact. Eur Heart J 1996; 17 Suppl. A: 8-15
3. Gascón JJ, Sánchez-Ortuno M, Llor B, et al. for the Treatment Compliance in Hypertension Study Group. Why hypertensive patients do not comply with the treatment: results from a qualitative study. Fam Pract 2004; 21 (2): 125-30
4. Herings RMC, Leufkens HGM, Heerdink ER, et al. Chronic pharmacotherapy continued: pharmo report [in Dutch]. The Hague: CIP data Royal Library, 2002
5. Psaty BM, Koepsell TD, Yanez ND, et al. Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992: an effect of the major clinical trials on clinical practice? JAMA 1995; 273: 1436-8
6. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on the persistence with antihypertensive treatment: the importance of actual practice data. Can Med Assoc J 1999; 16: 41-6
7. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and BP levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9
8. Rudd P, Byyny RL, Zachary V, et al. Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens 1988; 1: 309-12
9. Maenpaa H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur J Clin Pharmacol 1990; 38: 561-5
10. Roter DL. Hall JA, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998; 36: 1138-61
11. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to BP lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722-32
12. Takiya LN, Peterson AM, Finley RS. Meta-analysis of interventions for medication adherence to antihypertensives. Ann Pharmacother 2004; 38: 1617-24
13. Urquhart J. The electronic medication event monitoring: lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 245-56
14. Burnier M, Schneider MP, Chiolero A, et al. Electronic adherence monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001; 19: 335-41
15. Waeber B, Vetter W, Darioli R, et al. Improved BP control by monitoring adherence with antihypertensive treatment. Int J Clin Pract 1999; 53: 37-8
16. Cramer JA, Ouelette VL, Mattson RH. Effect of microelectronic observation on compliance. Epilepsia 1990; 31: 617-8
17. Bertholet N, Favrat B, Fallab-Studbi CL, et al. Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens 2000; 2 (4): 258-62
18. Bovet P, Burnier M, Madelaine G, et al. Monitoring one-year compliance to antihypertension medication in the Seychelles. Bull World Health Organ 2002; 80: 33-9
19. Leenen FHH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997; 13 (10): 914-20
20. Schwed A, Fallab C-L, Burnier M, et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999; 39: 402-9
21. Mallion JM, Dutrey-Dupagne C, Vaur L, et al. Benefits of electronic pillboxes in evaluating treatment compliance of patients with mild to moderate hypertension. J Hypertens, 1996; 14: 137-44
22. Cramer JA, Rosenbeck R. Enhancing medication compliance for people with serious mental illness. J Nerv Ment Dis 1999; 187: 53-5
23. Elixhauser A, Eisen SA, Romeis JC, et al. The effects of monitoring and feedback on compliance. Med Care 1990; 28: 882-93
24. Nides MA, Tadhkin DP, Simmons MS, et al. Improving inhaler adherence in a clinical trail through the use of the nebulizer chronology. Chest 1993; 104: 501-7
25. Schmitz JM, Sayre SL, Stotts AL, et al. Medication compliance during a smoking cessation trial: a brief intervention using MEMS feedback. J Behav Med 2005; 28 (2): 139-47
26. Cantor JC, Morisky DE, Green LW, et al. Cost-effectiveness of educational interventions to improve patient outcomes in BP control. Prevent Med 1985; 14: 782-800
27. Eastaugh SR, Hatcher ME. Improving compliance among hypertensives: a triage criterion with cost-benefit implications. Med Care 1982; 20: 1001-7
28. Logan AG, Milne BJ, Achber C, et al. Cost-effectiveness of a worksite hypertension treatment program. Hypertension 1981; 3: 211-8
29. Friedman RH, Kazis L, Jette A, et al. A telecommunications system for monitoring and counseling patients with hypertension: impact on medication adherence and BP control. Am J Hypertens 1996; 9: 285-92
30. Zarnke KB, Feagen BG, Mahon J, et al. A randomized study comparing a patient-directed hypertension management strategy with usual office-based care. Am J Hypertens 1997; 10: 58-7
31. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
32. Wetzels GEC, Nelemans PJ, Schouten JSAG, et al. Electronic monitoring of adherence as a tool to improve blood pressure control: a randomized controlled trial. Ann J Hypertens 2007 Feb; 20 (2): 119-25
33. Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601-15
34. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996
35. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programs. 3rd ed. Toronto: Oxford University Press, 2005
36. Goossens MEJB, Rutten-van Molken MP, Laeyen JW, et al. The cost diary: a method to measure direct and indirect costs in cost effectiveness research. J Clin Epidemiol 2000; 53: 688-95
37. Health Insurance Board (in Dutch) [online]. Available from URL: http://www.medicijnkosten.nl [Accessed 2005 May 25]
38. Kenniscentrum voor leren in de praktijk [online]. http://www.gobnet.nl [Accessed 2007 Jan 28]
39. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, et al. Manual for cost research, methods and standard cost prices for economic evaluations in health care. Diemen: Health Insurance Board, 2004
40. Klungel OH, de Boer A, Paes AHP, et al. Undertreatment of hypertension in a population-based study in The Netherlands. J Hypertens 1998; 16: 1371-8
41. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10 (5): 460-6
42. EuroQol-Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16 (3): 199-208
43. Dolan P. A social tariff for EuroQol: results from a UK population survey. York: University of York, 1995
44. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172-7
45. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005; 14 (5): 487-96
46. Little R, Rubin D. Statistical analysis with missing data. New York: Wiley, 1987
47. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6 (4): 327-40
48. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/Eratios alongside a clinical trial. Health Econ 1994; 3 (5): 309-19
49. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; Suppl. 18: S68-80
50. O'Brien BJ, Gertsen K, Willan AR, et al. Is there a kink in consumer's threshold value for cost-effectiveness in health care? Health Econ 2002; 11: 175-80
51. Severens JL, Brunenberg DEM, Fenwick EAL, et al. Cost-effectiveness acceptability curves and a reluctance to lose. Pharmacoeconomics 2005; 23 (12): 1207-14
52. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001; 10 (2): 179-84
53. Welte R, Feenstra T, Jager H, et al. Decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22 (13): 857-76